$IRON News

Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update

Disc Medicine Q2 EPS $(1.54) Beats $(1.77) Estimate

Disc Medicine: The CRL Has Created A Cleaner Bull Case

Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $85

Disc Medicine, Inc. (IRON) Discusses Clinical Updates on Bitopertin, Selcodebart, and DISC-3405 and Strategic Outlook Transcript

Disc Medicine, Inc. (IRON) Discusses Clinical Updates on Bitopertin, Selcodebart, and DISC-3405 and Strategic Outlook - Slideshow

Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting

Wedbush Reiterates Outperform on Disc Medicine, Maintains $88 Price Target

Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria

Disc Medicine Completes FDA Type A Meeting Regarding The Complete Response Letter To The New Drug Application For Bitopertin In Erythropoietic Protoporphyria; Data From APOLLO Phase 3 Study Expected In Q4 2026

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Disc Medicine Presents Updated Data From Myelofibrosis And Anemia Treatment RALLY-MF Phase 2 Trial Showing Reductions In Hepcidin And Higher Iron Levels, A Positive Clinical Impact On Anemia Measures Across A Broad Range Of Patient Types

How Investors May Respond To Disc Medicine (IRON) Expanding Pre-Approval Access To Bitopertin For Porphyria Patients

Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges

Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $80

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress

Disc Medicine to Participate in Upcoming Investor Conferences

A Look At Disc Medicine (IRON) Valuation After Legal Probes And FDA Complete Response Letter

Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update